September 30, 2021 | CRISPR, Impetus Digital, Jessica Schwaber, Natalie Yeadon, Solupore, allogeneic therapies, cell engineering, cell therapy, gene therapy, gene-editing, non-viral modalities, precision medicine, viral modalities
Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing the full potential of cell & gene therapy, and much more.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Even before the concept of physical/social distancing was born, Impetus Digital was a strong advocate for virtual collaboration. In our latest video, we explore another key benefit of asynchronous online…
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person.
At Impetus Digital, the health and wellbeing of our staff, clients, advisors, and their families is always our top priority. Recently, we have seen high numbers of advisors cancel their…
Impetus Digital shares its Top 10 list of the most important advisor questions.
Our online solutions are not just for advisory boards – find out how one client leveraged the Impetus InSite Platform® for a virtual journal club.
